IN2015DN02807A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02807A
IN2015DN02807A IN2807DEN2015A IN2015DN02807A IN 2015DN02807 A IN2015DN02807 A IN 2015DN02807A IN 2807DEN2015 A IN2807DEN2015 A IN 2807DEN2015A IN 2015DN02807 A IN2015DN02807 A IN 2015DN02807A
Authority
IN
India
Prior art keywords
crystalline phase
absd
disulfanediylbis
aminobutane
lysine
Prior art date
Application number
Inventor
Fabrice; Balavoine
Jean-Marie; Schneider
Gerard; Coquerel
Nicolas; Couvrat
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of IN2015DN02807A publication Critical patent/IN2015DN02807A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26Separation; Purification; Stabilisation; Use of additives
    • C07C319/28Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38Separation; Purification; Stabilisation; Use of additives
    • C07C227/40Separation; Purification
    • C07C227/42Crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a new crystalline phase of (3S, 3S' ) 4 ,4' disulfanediylbis(3- aminobutane 1 sulfonic acid) (ABSD) with L- lysine and its use , particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S, 3S' ) 4, 4'- disulfanediylbis(3- aminobutane 1 -sulfonic acid) (ABSD) with L -lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
IN2807DEN2015 2012-10-22 2013-10-22 IN2015DN02807A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306307.5A EP2722327A1 (en) 2012-10-22 2012-10-22 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
PCT/EP2013/072028 WO2014064077A1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine

Publications (1)

Publication Number Publication Date
IN2015DN02807A true IN2015DN02807A (en) 2015-09-11

Family

ID=47278723

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2807DEN2015 IN2015DN02807A (en) 2012-10-22 2013-10-22

Country Status (30)

Country Link
US (2) US9278921B2 (en)
EP (2) EP2722327A1 (en)
JP (1) JP6317358B2 (en)
KR (1) KR102103407B1 (en)
CN (1) CN104768927B (en)
AR (1) AR093070A1 (en)
AU (1) AU2013336738B2 (en)
BR (1) BR112015008931B1 (en)
CA (1) CA2884914C (en)
CY (1) CY1119913T1 (en)
DK (1) DK2909169T3 (en)
EA (1) EA024460B1 (en)
ES (1) ES2658413T3 (en)
HK (1) HK1212321A1 (en)
HR (1) HRP20180189T1 (en)
HU (1) HUE036037T2 (en)
IL (1) IL237733B (en)
IN (1) IN2015DN02807A (en)
LT (1) LT2909169T (en)
ME (1) ME02955B (en)
MX (1) MX353693B (en)
NO (1) NO2909169T3 (en)
NZ (1) NZ706070A (en)
PL (1) PL2909169T3 (en)
PT (1) PT2909169T (en)
RS (1) RS56896B1 (en)
SI (1) SI2909169T1 (en)
TW (1) TWI643842B (en)
WO (1) WO2014064077A1 (en)
ZA (1) ZA201503574B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951562B (en) * 2014-05-09 2016-04-20 四川九章生物化工科技发展有限公司 A kind of chlorogenic acid crystal formation and preparation method thereof
WO2022225712A1 (en) * 2021-04-22 2022-10-27 Teva Pharmaceuticals International Gmbh Solid state forms of firibastat and processes for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309336T3 (en) * 2002-07-16 2008-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) DERIVATIVES OF 4,4-DITIOBIS- (3-AMINOBUTAN-1-SULFANATES) NEW AND COMPOSITIONS THAT CONTAIN THEM.
FR2858617A1 (en) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med NOVEL 4 ', 4'-DITHIOBIS- (3-AMINOBUTANE-1-SULFONATE-1-SULFONATES) DERIVATIVES AND COMPOSITIONS CONTAINING SAME
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2439192A1 (en) 2010-10-07 2012-04-11 Quantum Genomics Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)
US9447050B2 (en) * 2011-04-05 2016-09-20 The Translational Genomics Research Institute Solid forms of curcumin

Also Published As

Publication number Publication date
CA2884914C (en) 2021-01-05
IL237733B (en) 2019-03-31
CN104768927A (en) 2015-07-08
HUE036037T2 (en) 2018-06-28
ZA201503574B (en) 2016-01-27
ME02955B (en) 2018-07-20
KR102103407B1 (en) 2020-04-22
DK2909169T3 (en) 2018-02-26
CN104768927B (en) 2017-06-09
CY1119913T1 (en) 2018-06-27
AU2013336738A1 (en) 2015-04-09
AU2013336738B2 (en) 2017-05-18
ES2658413T3 (en) 2018-03-09
HRP20180189T1 (en) 2018-04-20
RS56896B1 (en) 2018-04-30
LT2909169T (en) 2018-04-25
KR20150072454A (en) 2015-06-29
PT2909169T (en) 2018-02-26
US20150284325A1 (en) 2015-10-08
US20160221940A1 (en) 2016-08-04
AR093070A1 (en) 2015-05-13
JP2015536316A (en) 2015-12-21
BR112015008931A2 (en) 2017-07-04
NZ706070A (en) 2018-11-30
NO2909169T3 (en) 2018-06-02
HK1212321A1 (en) 2016-06-10
CA2884914A1 (en) 2014-05-01
EP2909169A1 (en) 2015-08-26
BR112015008931B1 (en) 2021-05-18
EA201500438A1 (en) 2015-09-30
WO2014064077A1 (en) 2014-05-01
MX353693B (en) 2018-01-24
US9487477B2 (en) 2016-11-08
TWI643842B (en) 2018-12-11
SI2909169T1 (en) 2018-04-30
EP2909169B1 (en) 2018-01-03
JP6317358B2 (en) 2018-04-25
EA024460B1 (en) 2016-09-30
PL2909169T3 (en) 2018-07-31
EP2722327A1 (en) 2014-04-23
TW201418202A (en) 2014-05-16
MX2015005059A (en) 2015-11-23
US9278921B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
CY1120805T1 (en) CRYSTAL FORMS SUSPENDER HYDROXYLASION PROYLO
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012076466A3 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MX2015003021A (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity.
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
MX340983B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
WO2012051407A3 (en) Molecular containers and methods of making and using same
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IN2011KN05169A (en)
IN2015DN02807A (en)
CA2901220C (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
WO2011152657A3 (en) Acetyl-l-carnitine malate, process for preparing the same, and pharmaceutical composition comprising the same
TN2014000106A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2013064326A3 (en) Arjunolic acid for increasing the production of sebum
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
UA99014C2 (en) Methyl ester of n-[(2-oxoindolinylidene-3)-2-oxyacetyl]aminoacetic acid exhibiting anti-inflammatory activity
MX2012013055A (en) Improved method for purifying the modified benzalkonium chloride and diallyl disulphide oxide complex and uses thereof.
UA105665C2 (en) 3-methylaminosuccinoylamido-n-(3&#39;,4&#39;-dimethylphenyl)anthranilic acid exhibiting high anti-inflammatory, analgetic, diuretic and antifungal activity